HRMY

SEC source: 0001104659-21-150129 · tm2135185-2_4seq1.xml · nonDerivative · entry 3

Jacobs John C · CIK 0001820836 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.20 to $38.69. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-150129 · tm2135185-2_4seq1.xml · nonDerivative · entry 2

Jacobs John C · CIK 0001820836 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,860

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $38.19. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-150129 · tm2135185-2_4seq1.xml · nonDerivative · entry 1

Jacobs John C · CIK 0001820836 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-148779 · tm2135185-1_4seq1.xml · nonDerivative · entry 2

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,545,243

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.09, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote three (3) of this Form 4.

F2 · ownership.nature: These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-21-148779 · tm2135185-1_4seq1.xml · nonDerivative · entry 1

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,547,828

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.37, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

F2 · ownership.nature: These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-21-144472 · tm2133953-2_4seq1.xml · derivative · entry 1

Szyper Linda M · CIK 0001739050 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,727

Underlying: Common Stock · 5,727 shares

Expires 2031-11-18

F1 · derivative.exercise_date: The stock option vests in 36 equal monthly installments beginning on December 18, 2021.

SEC source: 0001104659-21-140749 · tm2133295-1_4seq1.xml · nonDerivative · entry 3

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,572,511

F2 · ownership.nature: These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-21-140749 · tm2133295-1_4seq1.xml · nonDerivative · entry 2

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,573,928

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to 41.09, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (3) of this Form 4.

F2 · ownership.nature: These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001104659-21-140749 · tm2133295-1_4seq1.xml · nonDerivative · entry 1

Wicki Andreas · CIK 0001511472 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,609,179

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.80 to $42.91, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission, full information regarding the shares sold at each separate price within the ranges set forth in footnote one (1) of this Form 4.

F2 · ownership.nature: These shares are held by HBM Healthcare Investments (Cayman) Ltd. ("HBM"), of which Mr. Wicki is a member of the board of directors. The board of directors of HBM acts by majority vote, and Mr. Wicki does not have sole voting or investment power with respect to the shares. Mr. Wicki disclaims beneficial ownership of such shares for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that the reporting person is a beneficial owner for the purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000899243-21-042746 · doc4.xml · derivative · entry 5

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,476

Underlying: Common Stock · 3,952 shares

Expires 2030-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares in four equal annual installments beginning on March 1, 2022.

SEC source: 0000899243-21-042746 · doc4.xml · derivative · entry 4

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,429

Underlying: Common Stock · 6,048 shares

Expires 2027-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 3,690 shares, and will vest with respect to the remainder of the shares on October 1, 2022.

F5 · balance_after: Reflects 785 additional stock options which were erroneously reported as exercised on the Form 4 filed by the reporting person on September 3, 2021, but which were actually exercised from the tranche which expires on October 1, 2028.

SEC source: 0000899243-21-042746 · doc4.xml · nonDerivative · entry 3

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.03 to $43.00. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-042746 · doc4.xml · nonDerivative · entry 2

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,946

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $42.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-042746 · doc4.xml · nonDerivative · entry 1

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · derivative · entry 6

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,469

Underlying: Common Stock · 4,101 shares

Expires 2027-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021.

SEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · derivative · entry 5

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,570

Underlying: Common Stock · 14,099 shares

Expires 2027-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021.

SEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 4

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.70 to $43.99. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 3

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 2

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.65 to $43.63. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 1

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-21-124273 · tm2129561-1_4seq1.xml · derivative · entry 3

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,669

Underlying: Common Stock · 1,800 shares

Expires 2027-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021.

SEC source: 0001104659-21-124273 · tm2129561-1_4seq1.xml · nonDerivative · entry 2

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.075 to $40.41. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-21-124273 · tm2129561-1_4seq1.xml · nonDerivative · entry 1

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035891 · doc4.xml · derivative · entry 3

Jacobs John C · CIK 0001820836 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,751

Underlying: Common Stock · 25,000 shares

Expires 2027-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is currently vested with respect to 188,851 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 1, 2021.

SEC source: 0000899243-21-035891 · doc4.xml · nonDerivative · entry 2

Jacobs John C · CIK 0001820836 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.45 to $36.38. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035891 · doc4.xml · nonDerivative · entry 1

Jacobs John C · CIK 0001820836 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035505 · doc4.xml · derivative · entry 3

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,469

Underlying: Common Stock · 10,000 shares

Expires 2027-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021.

SEC source: 0000899243-21-035505 · doc4.xml · nonDerivative · entry 2

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.78. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035505 · doc4.xml · nonDerivative · entry 1

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035508 · doc4.xml · derivative · entry 4

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,428

Underlying: Common Stock · 917 shares

Expires 2030-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is currently vested with respect to 4,869 shares, and will vest with respect to the remainder of the shares in four equal annual installments beginning on March 1, 2022.

SEC source: 0000899243-21-035508 · doc4.xml · derivative · entry 3

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,304

Underlying: Common Stock · 4,083 shares

Expires 2028-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is currently vested with respect to 4,868 shares, and will vest with respect to the remainder of the shares in three equal annual installments beginning on October 1, 2021.

F4 · balance_after: Reflects the exercise of 785 stock options on September 1, 2021, which was reported on the Form 4 filed by the reporting person on September 3, 2021, but erroneously reflected as an exercise of the tranche which expires on October 2, 2027, rather than the tranche which expires on October 1, 2028.

SEC source: 0000899243-21-035508 · doc4.xml · nonDerivative · entry 2

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-21-035508 · doc4.xml · nonDerivative · entry 1

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-035132 · doc4.xml · derivative · entry 4

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,692

Underlying: Common Stock · 10,000 shares

Expires 2027-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 20,707 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 2, 2021.

SEC source: 0000899243-21-035132 · doc4.xml · nonDerivative · entry 3

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $ 33.95 to $34.69. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035132 · doc4.xml · nonDerivative · entry 2

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,302

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.90 to $33.63. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-035132 · doc4.xml · nonDerivative · entry 1

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-034517 · doc4.xml · derivative · entry 6

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,469

Underlying: Common Stock · 7,841 shares

Expires 2027-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021.

SEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 4

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.43. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 3

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-034515 · doc4.xml · derivative · entry 6

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,692

Underlying: Common Stock · 3,400 shares

Expires 2027-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 20,707 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 2, 2021.

SEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 4

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.045. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 3

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-034517 · doc4.xml · derivative · entry 5

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,310

Underlying: Common Stock · 2,159 shares

Expires 2027-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021.

SEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 2

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.09. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 1

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,159

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-034515 · doc4.xml · derivative · entry 5

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,092

Underlying: Common Stock · 1,600 shares

Expires 2027-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is currently vested with respect to 20,707 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 2, 2021.

SEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 2

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.045. The reporting person undertakes to provide the issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-21-034515 · doc4.xml · nonDerivative · entry 1

Dierks Jeffrey · CIK 0001821102 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-21-032526 · doc4.xml · derivative · entry 3

Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,469

Underlying: Common Stock · 9,950 shares

Expires 2027-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021.